eleclazine
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2013 (NCT01847391)
Timeline
Indications
Mechanism of action
SCN5A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1- Mol. weight
- 415.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707392 ↗
Also known as
- eleclazine
- eleclazine
- eleclazine
- eleclazine
- gs-6615
- gs-6615
- gs-6615
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02365506 | Phase 1 | Jul 1, 2015 | Gilead Sciences |
| NCT02441829 | Phase 1 | May 1, 2015 | Gilead Sciences |
| NCT02377336 | Phase 2 | May 1, 2015 | Gilead Sciences |
| NCT02412098 | Phase 1 | Mar 1, 2015 | Gilead Sciences |
| NCT02291237 | Phase 2/Phase 3 (Phase 3) | Feb 5, 2015 | Gilead Sciences |
| NCT02365532 | Phase 1 | Feb 1, 2015 | Gilead Sciences |
| NCT02300558 | Phase 3 | Dec 17, 2014 | Gilead Sciences |
| NCT02104583 | Phase 2 | Sep 1, 2014 | Gilead Sciences |
| NCT01849003 | Phase 1 | May 1, 2013 | Gilead Sciences |
| NCT01847391 | Phase 1 | May 1, 2013 | Gilead Sciences |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 10 | 10 | 3 | 2013 |
1 organizations
Page 1 / 1